FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial. PMID 38335141 · Anesth Analg · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Psycho-oncology/Supportive Care in Head-Neck Cancers Patients Undergoing Radiation Therapy: A Randomized Controlled Trial. PMID 41426184 · South Asian J Cancer · 2025-Apr The trial is a randomized controlled trial in human oncology patients, but it does not meet the primary eligibility criteria. The intervention is psycho-oncology/palliative/supportive care referral (non-drug), and the primary endpoint is distress proportion (not a time-to-event endpoint like OS/PFS/DFS). Although survival endpoints are mentioned as having no significant difference, the report does not focus on or provide data for a primary/key secondary time-to-event efficacy endpoint suitable for Kaplan-Meier digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Clinical efficacy of endocrinotherapy combined with Shenqi Pills on patients with hormone-sensitive prostate cancer]. PMID 40787962 · Zhonghua Nan Ke Xue · 2025-Apr The study is a randomized oncology trial in humans with a primary OS endpoint, but it is ineligible because the intervention combines a standard drug therapy with a Chinese herbal product (Shenqi Pills), which does not meet the strict 'drug-containing intervention' criterion for conventional drugs. Additionally, the trial phase is not explicitly reported as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Clinical efficacy of prostatectomy combined with neoadjuvant endocrine therapy]. PMID 40787958 · Zhonghua Nan Ke Xue · 2025-Apr The record describes a randomized controlled trial in oncology (prostate cancer) with a drug-containing intervention (neoadjuvant endocrine therapy). However, it does not report a primary or key secondary time-to-event efficacy endpoint such as overall survival, progression-free survival, disease-free survival, event-free survival, recurrence-free survival, time to progression, or any Kaplan-Meier or hazard ratio analysis. The outcomes reported are clinical indicators, immune function, serum markers, complications, and a non-formal one-year recurrence rate. Therefore, it does not meet the eligibility requirement for a time-to-event efficacy endpoint. The phase is not explicitly stated, so phase3_or_definitive is null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Metformin for recurrent colorectal polyp or adenoma prevention after polypectomy in patients without diabetes mellitus: a prospective study. PMID 40353629 · Neoplasma · 2025-Apr The study is a randomized, oncology, human, drug-intervention trial with original results, but it is excluded because the primary endpoint is not a time-to-event outcome (it is a binary proportion of adenoma recurrence at 1 year). There is no signal for OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. PMID 40337868 · Immunotherapy · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Japanese participant data from three gantenerumab trials in early Alzheimer's disease. PMID 40302041 · Alzheimers Dement · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiac myosin inhibition in hypertrophic cardiomyopathy: review of the evolving evidence base. PMID 40285342 · Expert Rev Cardiovasc Ther · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of colonoscopy screening on risks of colorectal cancer and related death: instrumental variable estimation of per-protocol effects. PMID 40278966 · Eur J Epidemiol · 2025-Apr The study is an oncology randomized trial (NordICC) evaluating colonoscopy screening for colorectal cancer prevention, with cancer incidence and mortality as primary endpoints. While it meets criteria for being oncology, human, randomized, and an original result, it does not contain a drug intervention (colonoscopy is a procedural/screening intervention, not a drug). Therefore, it fails the drug-intervention criterion and is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study. PMID 40271888 · Alzheimers Dement · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy. PMID 40268743 · Cancer Invest · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Oral Levofloxacin Versus Amoxicillin-Clavulanate/Ciprofloxacin for Outpatient Management of Low-Risk Febrile Neutropenia in Children With Cancer in Egypt. PMID 40267379 · JCO Glob Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Three-field vs two-field lymphadenectomy in thoracic ESCC patients: a multicenter randomized study (NST 1503). PMID 40265094 · J Natl Cancer Cent · 2025-Apr The study is an oncology randomized trial with time-to-event endpoints (OS, DFS) and reports original results. However, the intervention is purely surgical (lymphadenectomy techniques) and does not involve a drug-containing intervention, which is a required criterion for eligibility. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata or abstract text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs. PMID 40265093 · J Natl Cancer Cent · 2025-Apr The record describes a methodological study validating a surrogate endpoint (PFS36 for OS) by analyzing aggregated data from multiple existing Phase III radiotherapy trials. It is not an original result report from a single randomized trial with a drug-containing intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma. PMID 40264918 · JCO Oncol Adv · 2025-Apr Record fails required criteria due to missing abstract content, which prevents verification of human subjects and the presence of a time-to-event efficacy endpoint. The title suggests eligibility, but without an abstract, we cannot confirm the report contains original results or that a time-to-event endpoint is reported. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials. PMID 40260308 · Crohns Colitis 360 · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Fixed-dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Black Participants with Moderate to Severe Acne. PMID 40256338 · J Clin Aesthet Dermatol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of a Single Preventive Intravenous Dose of Ketorolac and Paracetamol on Reducing Postoperative Pain in Septorhinoplasty Patients: Double-Blind Randomized Clinical Trial. PMID 40255229 · Iran J Med Sci · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial. PMID 40247887 · EClinicalMedicine · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. PMID 40242562 · EClinicalMedicine · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. PMID 40241307 · Eur J Neurol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial. PMID 40230305 · Health Technol Assess · 2025-Apr The record is a prospective prognostic model study in colorectal cancer, not a randomized drug intervention trial. It is an observational cohort evaluating biomarkers and imaging for prognosis, lacking randomization, a drug intervention, and a therapeutic efficacy endpoint. The deterministic review correctly flagged unclear Phase III evidence, and deeper analysis confirms ineligibility based on core criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice. PMID 40230191 · Pharmacol Res Perspect · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Symptom Attribution, Help Seeking and Willingness to Undergo Diagnostic Investigations for Bowel Cancer Symptoms in People With Anxiety and/or Depression-A Vignette Study. PMID 40220329 · Psychooncology · 2025-Apr The study is a randomized vignette study investigating symptom attribution, help-seeking, and willingness to undergo diagnostic tests for bowel cancer symptoms in people with anxiety/depression. It is an oncology-related human study but lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). It is not a Phase III/IIIb or Phase II/III drug efficacy trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study. PMID 40214296 · J Diabetes · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024. PMID 40212179 · Ann Med Surg (Lond) · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. PMID 40209141 · JCO Precis Oncol · 2025-Apr The report is a secondary, retrospective biomarker subgroup analysis of the PENELOPE-B trial, not the original primary result report of the trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis. PMID 40204996 · Nat Cancer · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Combined Treatment With Cognitive Behavioral Therapy for Insomnia and Acceptance and Commitment Therapy Enhances Objective and Subjective Reports of Sleep in Patients With Advanced Cancer. PMID 40204663 · Psychooncology · 2025-Apr The study is an oncology, human, randomized trial with original results, but it is not a Phase III/IIIb or Phase II/III drug intervention trial (it is a non-drug cognitive-behavioral therapy pilot study) and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC". PMID 40204397 · J Thorac Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Response to "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC". PMID 40204396 · J Thorac Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled 'REAL-FITNESS' Trial to Evaluate Physical Activity in Patients With Newly Diagnosed Multiple Myeloma. PMID 40196920 · J Cachexia Sarcopenia Muscle · 2025-Apr The trial is a randomized, oncology study with human patients and reports original results including a time-to-event endpoint (event-free survival). However, it is not eligible because the intervention is primarily exercise/physical activity, not a drug-containing intervention. The study evaluates exercise during standard drug therapy (VCd), but the drug regimen is the control/background therapy, not the experimental intervention. The phase of the trial is not explicitly stated as Phase III or definitive in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Storytelling Through Music With Parents Whose Children Have Died From Cancer: A Randomized Controlled Feasibility Trial. PMID 40195024 · Psychooncology · 2025-Apr The study is a randomized feasibility trial of a psychosocial bereavement intervention for parents of children who died from cancer. It is not a drug intervention trial, does not evaluate a cancer therapeutic, and does not use time-to-event efficacy endpoints (OS, PFS, etc.) or Kaplan-Meier/HR analyses. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Combined Data From Three Clinical Trials. PMID 40192160 · ACR Open Rheumatol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial. PMID 40180472 · Lancet HIV · 2025-Apr The study is a randomized, placebo-controlled Phase III trial (REPRIEVE) with drug intervention and time-to-event endpoints, but it is not an oncology trial. Its primary focus is cardiovascular disease prevention in people with HIV. The cancer-related endpoint (non-AIDS-defining cancer) is only a component of a composite secondary endpoint (START outcome), not the primary or key secondary efficacy endpoint for an oncology indication. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort requiring a trial for human malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review. PMID 40175003 · Lancet Haematol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial. PMID 40175001 · Lancet Haematol · 2025-Apr The trial is a randomized, open-label study in human oncology (chronic lymphocytic leukaemia) with a drug intervention (BTK inhibitors). However, it is a Phase II trial (not Phase III/IIIb or Phase II/III as defined) and the primary efficacy endpoint is immunogenicity (anti-spike antibody titre), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. PMID 40172303 · Alzheimers Dement · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib. PMID 40165400 · Cancer Med · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Summary of Research: Comparable Efficacy and Safety of Brodalumab in Obese and Nonobese Patients with Psoriasis: Analysis of Two Randomized Controlled Trials. PMID 40156694 · Clin Drug Investig · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Low-Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double-Blind Randomized Clinical Trial. PMID 40152076 · Cancer Med · 2025-Apr Study is a randomized, double-blind, drug-intervention (fluconazole) trial in acute leukemia (oncology/human) reporting original results. However, it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier analysis or hazard ratio. Outcomes focus on infection incidence, colonization, and adverse events, not time-to-event survival. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. PMID 40147459 · Lancet Oncol · 2025-Apr The trial is ineligible because it does not have a drug-containing intervention and does not have a primary or key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up). PMID 40147400 · Lung Cancer · 2025-Apr The study is a randomized, multi-center, non-inferiority trial in oncology with human subjects and time-to-event endpoints (OS, DFS). However, it does not involve a drug-containing intervention; it compares diagnostic/surgical strategies (endosonography with or without confirmatory mediastinoscopy). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study. PMID 40145508 · Future Oncol · 2025-Apr The record describes a randomized phase 3 oncology trial with human patients and likely drug intervention, and the podcast discusses original results. However, the abstract does not explicitly state a time-to-event endpoint (e.g., OS, PFS) or confirm drug intervention details for strict eligibility. The publication type is also non-standard for formal result reporting. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. PMID 40140623 · Nat Med · 2025-Apr Eligibility cannot be determined because the record is a published erratum (correction) for a trial, not the original result report itself. The provided metadata lacks an abstract or any content describing study outcomes, making it impossible to confirm the presence of a primary/key secondary time-to-event efficacy endpoint, which is a required criterion for inclusion. Metadata does not establish human subject participation. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics. PMID 40139025 · Gynecol Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study. PMID 40130421 · Future Oncol · 2025-Apr The record is an eligible-type trial (Phase III, randomized, drug intervention, oncology, human) but is a podcast discussing design and rationale, not an original formal result report with a time-to-event efficacy endpoint. Therefore, it is excluded as not meeting the 'original_result' criterion and lacking a 'time_to_event' signal in this record. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial. PMID 40123793 · EJHaem · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. PMID 40120616 · Lancet Neurol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Psychometric Validation of the Subject Sleep Diary in Patients with Moderate-to-Severe Atopic Dermatitis. PMID 40116983 · Dermatol Ther (Heidelb) · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |